Sequence information
DRAVP ID DRAVPc029
Name Bamlanivimab(LY-3819253,LY-CoV555)
Sequence Not available
Molecular Formula C6498H10068N1732O2032S46
Condition/Disease COVID-19
Group Approved
Type Antibody
Description Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19. Bamlanivimab is a neutralizing IgG1κ mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells. Under the EUA granted in February 2021, bamlanivimab is used in combination with etesevimab to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for progressing to severe COVID-19.The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.
Active sequence/Structure
External Links
DrugBank Accession Number DB15718
Pubchem ID 434370493
CHEMBL ID CHEMBL4650379
UNII 45I6OFJ8QH
CAS 2423943-37-5
ClinicalTrails Information
| NCT Number | Study Title | Condition/Disease | Status | Phase | Sponsor |
|---|---|---|---|---|---|
| NCT04634409 | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4) | Coronavirus Disease 2019 (COVID‑19) Treatment | Completed | Phase 2 | Eli Lilly and Company |
| NCT04701658 | A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19) (BLAZE-5) | Coronavirus Disease 2019 (COVID‑19) Treatment | Completed | Phase 2 | Eli Lilly and Company |
| NCT04497987 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2) | Coronavirus Disease 2019 (COVID‑19) Prevention | Completed | Phase 3 | Eli Lilly and Company |
| NCT04656691 | At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19 | Coronavirus Disease 2019 (COVID‑19) Treatment | Terminated (In April 2021 FDA revoked the Emergency Use Authorization after determining that the kno | Phase 4 | Daniel Griffin |
| NCT04790786 | UPMC OPTIMISE-C19 Trial, a COVID-19 Study (OPTIMISE-C19) | Coronavirus Disease 2019 (COVID‑19) | Completed | Phase 4 | Erin McCreary |
